Grifols (GRFS) Cash & Equivalents (2009 - 2025)

Grifols (GRFS) posted Cash & Equivalents of $923.1 million for Q4 2025, down 11.85% quarter-over-quarter from $1.0 billion in Q4 2024, and down 11.85% year-on-year from $1.0 billion in Q4 2024.

Grifols (GRFS) Cash & Equivalents (2009 - 2025) Analysis & Trends

Grifols (GRFS) has reported Cash & Equivalents for 16 consecutive years, with $923.1 million the latest figure, recorded in Q4 2025.

  • Cash & Equivalents for Q4 2025 came in at $923.1 million, down 11.85% year-over-year; the trailing twelve-month figure through Dec 2025 was $923.1 million (down 11.85% YoY), and the FY2025 annual result was $923.1 million, down 11.85% from the prior year.
  • Cash & Equivalents was $923.1 million for Q4 2025 at Grifols, down from $1.0 billion in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $3.1 billion in Q4 2021 and troughed at $560.1 million in Q4 2022.
  • Average Cash & Equivalents over 5 years is $1.2 billion, with a median of $923.1 million recorded in 2025.
  • Year-over-year, Cash & Equivalents surged 342.97% in 2021 and slumped 81.7% in 2022.
  • Over 5 years, Cash & Equivalents stood at $3.1 billion in 2021, then plunged by 81.7% to $560.1 million in 2022, then gained by 1.62% to $569.2 million in 2023, then soared by 83.99% to $1.0 billion in 2024, then dropped by 11.85% to $923.1 million in 2025.
  • Per Business Quant data, the three most recent Cash & Equivalents figures were $923.1 million in Q4 2025, $1.0 billion in Q4 2024, and $569.2 million in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 5.28 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 21.69 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 9.39 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 7.56 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 5.33 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 12.04 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 7.63 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 1.70 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Grifols - - - 923.09 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 923.09 Mn
Dec 31, 2024 1.05 Bn
Dec 31, 2023 569.17 Mn
Dec 31, 2022 560.12 Mn
Dec 31, 2021 3.06 Bn
Dec 31, 2020 691.11 Mn
Sep 30, 2020 1.21 Bn
Mar 31, 2020 703.98 Mn
Dec 31, 2019 821.29 Mn
Sep 30, 2019 881.43 Mn
Mar 31, 2019 655.51 Mn
Dec 31, 2018 1.18 Bn
Sep 30, 2018 676.95 Mn
Jun 30, 2018 797.82 Mn
Mar 31, 2018 1.04 Bn
Dec 31, 2017 1.04 Bn
Jun 30, 2017 824.90 Mn
Dec 31, 2016 966.36 Mn
Sep 30, 2016 1.01 Bn
Jun 30, 2016 911.83 Mn